Autologous peripheral blood stem cell transplantation for lung cancer.
Lung carcinoma, the most frequent cause of cancer-related death in both men and women, remains a difficult therapeutic problem. Small-cell lung carcinoma, despite its high response rate to chemotherapy, is associated with a rapid recurrence and ultimately limited overall survival. In attempts to exploit tumour chemosensitivity, high-dose chemotherapy (HDC) combining several active drugs has been studied to improve outcome. In addition, haematopoietic stem cell support has been used to allow dose escalation without major myelosuppression. In contrast to small-cell carcinoma, non-small-cell carcinoma of the lung is generally not very responsive to chemotherapy, and results with dose intensity in unresectable tumour have so far been very disappointing. We review the results of HDC in terms of response and survival, and discuss potential strategies to improve the effectiveness of dose intensity.
Guillaume
T
T
University Hospital St Luc and Laboratory of Experimental Oncology and Hematology, Université Catholique de Louvain, Brussels, Belgium.
Rubinstein
D B
DB
Zaner
K S
KS
Humblet
Y
Y
Symann
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000592:standards; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D009360:Neoplastic Cells, Circulating; D014182:Transplantation, Autologous / Q000379:methods / Q000592:standards; D016896:Treatment Outcome